Evogene Ltd. (EVGN) Misses Q3 EPS by 6c

Evogene Ltd. (NYSE: EVGN) reported Q3 EPS of ($0.17), $0.06 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $3.16 million versus the consensus estimate of $4.2 million.

For earnings history and earnings-related data on Evogene Ltd. (EVGN) click here.

You May Also Be Interested In

• Evogene (EVGN) Tops Q2 EPS by 15c
• Bath & Body Works rises as Citi upgrades stock ahead of earnings
• Enhanced Group plans AI health platform launch in 2026